case_images: PMC11834364_01
case_images: Endoscopic and histopathological findings of the stomach at diagnosis of eosinophilic gastroenteritis (EGE). (A-C) Esophagogastroduodenoscopy at diagnosis of EGE demonstrates mucosal edema, redness, erosion, and multiple nodules (arrows) in the stomach (A: antrum, B: body, C: cardia). (D) Histological findings of biopsy specimens from the stomach show marked eosinophilic infiltration (hematoxylin and eosin staining, x400).
case_images: ir-2024-00013f1.jpg
case_images: PMC11834364_01_ir-2024-00013f1.jpg
case_images: f1-ir-2024-00013
case_images: Esophagogastroduodenoscopy revealed diffuse mucosal edema with patchy redness, multiple erosions and nodularity of the stomach (Fig. 1A-C). Histologic examination of the bioptic specimens from the stomach showed marked eosinophilic infiltration (eosinophil counts > 60/high-powered field) (Fig. 1D).
case_images: Endoscopic and histopathological findings of the colon before vedolizumab therapy. (A, B) Ileocolonoscopy before vedolizumab therapy demonstrates reddish friable mucosa with purulent mucus in the left side colon (A: descending colon, B: rectum). (C) Histological findings of biopsy specimens from the descending colon show increased eosinophilic infiltration (hematoxylin and eosin staining, x400).
case_images: ir-2024-00013f2.jpg
case_images: PMC11834364_01_ir-2024-00013f2.jpg
case_images: f2-ir-2024-00013
case_images: Ileocolonoscopy demonstrated reddish friable mucosa with purulent mucus in the left side of the colon (Fig. 2A and B). Histological examination of the colonic bioptic specimens revealed increased eosinophilic infiltration along with chronic inflammatory cells infiltration (eosinophil counts > 20/high-powered field) (Fig. 2C).
case_images: Endoscopic and histopathological findings of the stomach after vedolizumab therapy. (A-C) Esophagogastroduodenoscopy 1 year after the initiation of vedolizumab demonstrates improvement of gastric mucosal abnormalities (A: antrum, B: body, C: cardia). (D) Histological findings of biopsy specimens from the stomach demonstrate decreased level of eosinophilic infiltration (hematoxylin and eosin staining, x 400).
case_images: ir-2024-00013f3.jpg
case_images: PMC11834364_01_ir-2024-00013f3.jpg
case_images: f3-ir-2024-00013
case_images: Expectedly, his upper and lower abdominal symptoms improved and he subsequently maintained clinical remission. Esophagogastroduodenoscopy and ileocolonoscopy with biopsy 1 year after the induction of vedolizumab demonstrated endoscopic improvement of the stomach (Fig. 3A-C) and colon (Fig. 4A and B) with decreased eosinophilic infiltration in both organs (Figs. 3D, 4C).
case_images: Endoscopic and histopathological findings of the colon after vedolizumab therapy. (A, B) Ileocolonoscopy after vedolizumab therapy demonstrates endoscopic remission of UC (A: descending colon, B: rectum). (C) Histological findings of biopsy specimens from the descending colon show reduced eosinophil infiltration (hematoxylin and eosin staining, x400).
case_images: ir-2024-00013f4.jpg
case_images: PMC11834364_01_ir-2024-00013f4.jpg
case_images: f4-ir-2024-00013
case_images: Expectedly, his upper and lower abdominal symptoms improved and he subsequently maintained clinical remission. Esophagogastroduodenoscopy and ileocolonoscopy with biopsy 1 year after the induction of vedolizumab demonstrated endoscopic improvement of the stomach (Fig. 3A-C) and colon (Fig. 4A and B) with decreased eosinophilic infiltration in both organs (Figs. 3D, 4C).